lovastatin has been researched along with Liver Diseases in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hamirani, YS; Jones, PH; Vasudevan, AR | 1 |
| Alsheikh-Ali, AA; Karas, RH | 1 |
| Alsheikh-Ali, AA; Han, H; Karas, RH; Maddukuri, PV | 1 |
| Ackerson, L; Avins, AL; Hwang, PM; Levin, TR; Levine, JG; Manos, MM; Murphy, R; Replogle, A; Watson, DJ; Zhao, W | 1 |
| Golov, KG; Ivanov, AA; Neverov, NI; Polyakov, AN; Tareyeva, IE | 1 |
| Asenjo-Barrón, JC; Cárdenas-Vásquez, R; Díaz-Zagoya, JC; Juárez-Oropeza, MA; Martínez, F | 1 |
| Tolman, KG | 1 |
3 review(s) available for lovastatin and Liver Diseases
| Article | Year |
|---|---|
Safety of statins: effects on muscle and the liver.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; C-Reactive Protein; Chemical and Drug Induced Liver Injury; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver; Liver Diseases; Lovastatin; Muscle, Skeletal; Rhabdomyolysis | 2005 |
Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials.
Topics: Chemical and Drug Induced Liver Injury; Cholesterol, LDL; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Indoles; Liver Diseases; Lovastatin; Neoplasms; Pravastatin; Rhabdomyolysis; Simvastatin | 2007 |
Defining patient risks from expanded preventive therapies.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Incidence; Liver; Liver Diseases; Lovastatin; Risk Factors; United States | 2000 |
4 other study(ies) available for lovastatin and Liver Diseases
| Article | Year |
|---|---|
Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
Topics: Adverse Drug Reaction Reporting Systems; Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Prescriptions; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver Diseases; Lovastatin; Niacin; Pravastatin; Prevalence; Pyrroles; Retrospective Studies; Rhabdomyolysis; Risk Factors; Simvastatin; United States; United States Food and Drug Administration | 2007 |
Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Cohort Studies; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Diseases; Liver Function Tests; Lovastatin; Male; Middle Aged; Retrospective Studies; Risk Assessment | 2008 |
Effects of dietary lipids and lovastatin during the course of nephropathies.
Topics: Adult; Aged; Dietary Fats; Female; Humans; Liver Diseases; Lovastatin; Male; Middle Aged | 1995 |
High lovastatin doses combined with hypercholesterolemic diet induce hepatic damage and are lethal to the CD-1 mouse.
Topics: Animals; Anticholesteremic Agents; Chemical and Drug Induced Liver Injury; Cholesterol; Cholesterol, Dietary; Dose-Response Relationship, Drug; Female; Lipids; Liver; Liver Diseases; Lovastatin; Male; Mice; Sex Factors; Triglycerides | 1999 |